PEDIARIX: Clinical Trials

10 trials of PEDIARIX, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 1 recruiting. 10 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 310Completed 9, Recruiting 1

Follow PEDIARIX: new trials by email Literature Review of PEDIARIX trials Research Report on PEDIARIX

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
Multivalent Group B streptococcus vaccine, Placebo, Infanrix hexa - Healthy
Phase 3RecruitingPfizer60002025-08-252026-10-27
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix - Infections, Meningococcal
Phase 3CompletedGlaxoSmithKline11962018-07-272026-08-20
This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine
Rotarix, Pediarix, Hiberix - Rotavirus Infection, Rotavirus Vaccines
Phase 3CompletedGlaxoSmithKline12802017-09-142020-12-29
Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants
Infanrix hexa, Pediarix, ActHIB - Poliomyelitis, Diphtheria
Phase 3CompletedGlaxoSmithKline5852014-04-162019-11-27
Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix® - Neisseria Meningitidis, Haemophilus Influenzae Type b
Phase 3CompletedGlaxoSmithKline6002014-02-012018-09-14
Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants
GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™ - Haemophilus Influenzae Type b
Phase 3CompletedGlaxoSmithKline40032010-06-182018-07-12
Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix® - Infections, Meningococcal
Phase 3CompletedGlaxoSmithKline15582008-02-132018-09-21
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib - Meningitis, Meningococcal
Phase 3CompletedNovartis Vaccines45452007-03-012014-03-24
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta - Haemophilus Influenzae Type b, Neisseria Meningitidis
Phase 3CompletedGlaxoSmithKline44322006-09-012016-12-16
Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB - Haemophilus Influenzae Type b, Neisseria Meningitidis
Phase 3CompletedGlaxoSmithKline44412006-02-222018-08-24

Conditions studied

Haemophilus Infections (5)  ·  Meningococcal Infections (4)  ·  Meningitis (2)  ·  Meningitis, Meningococcal (2)  ·  Diphtheria (1)  ·  Gram-Negative Bacterial Infections (1)  ·  Hepatitis B (1)  ·  Poliomyelitis (1)  ·  Rotavirus Infections (1)  ·  Tetanus (1)

Sponsors

GlaxoSmithKline (8)  ·  Novartis Vaccines (1)  ·  Pfizer (1)

Countries

United States (10)  ·  Mexico (3)  ·  Argentina (2)  ·  Australia (1)  ·  Brazil (1)  ·  Canada (1)  ·  Colombia (1)  ·  Finland (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Philippines (1)  ·  Puerto Rico (1)  ·  South Africa (1)  ·  South Korea (1)  ·  Spain (1)

Results publications

PMID 22094635, PMID 22327493, PMID 25152325, PMID 25305567

NIH funding

2016 (2)